Skip to Content
Merck
  • Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs.

Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs.

Vaccine (2014-06-17)
Lauren K Woolley, Shayne A Fell, Jocelyn R Gonsalves, Benjamin B A Raymond, Damian Collins, Tracey A Kuit, Mark J Walker, Steven P Djordjevic, Graeme J Eamens, Cheryl Jenkins
ABSTRACT

Pig responses to recombinant subunit vaccines containing fragments of eight multifunctional adhesins of the Mycoplasma hyopneumoniae (Mhp) P97/P102 paralog family formulated with Alhydrogel(®) or Montanide™ Gel01 were compared with a commercial bacterin following experimental challenge. Pigs, vaccinated intramuscularly at 9, 12 and 15 weeks of age with either of the recombinant formulations (n=10 per group) or Suvaxyn(®) M. hyo (n=12), were challenged with Mhp strain Hillcrest at 17 weeks of age. Unvaccinated, challenged pigs (n=12) served as a control group. Coughing was assessed daily. Antigen-specific antibody responses were monitored by ELISA in serum and tracheobronchial lavage fluid (TBLF), while TBLF was also assayed for cytokine responses (ELISA) and bacterial load (qPCR). At slaughter, gross and histopathology of lungs were quantified and damage to epithelial cilia in the porcine trachea was evaluated by scanning electron microscopy. Suvaxyn(®) M. hyo administration induced significant serological responses against Mhp strain 232 whole cell lysates (wcl) and recombinant antigen F3P216, but not against the remaining vaccine subunit antigens. Alhydrogel(®) and Montanide™ Gel01-adjuvanted antigen induced significant antigen-specific IgG responses, with the latter adjuvant eliciting comparable Mhp strain 232 wcl specific IgG responses to Suvaxyn(®) M. hyo. No significant post-vaccination antigen-specific mucosal responses were detected with the recombinant vaccinates. Suvaxyn(®) M. hyo was superior in reducing clinical signs, lung lesion severity and bacterial load but the recombinant formulations offered comparable protection against cilial damage. Lower IL-1β, TNF-α and IL-6 responses after challenge were associated with reduced lung lesion severity in Suvaxyn(®) M. hyo vaccinates, while elevated pathology scores in recombinant vaccinates corresponded to cytokine levels that were similarly elevated as in unvaccinated pigs. This study highlights the need for continued research into protective antigens and vaccination strategies that will prevent Mhp colonisation and establishment of infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Carbon, mesoporous, nanopowder, graphitized, less than 250 ppm Al, Ti, Fe, Ni, Cu, and Zn combined
Sigma-Aldrich
Carbon, mesoporous, less than 100 ppm Al, Ti, Fe, Ni, Cu, and Zn combined
Sigma-Aldrich
Carbon, mesoporous, nanopowder, less than 500 ppm Al, Ti, Fe, Ni, Cu, and Zn combined
Sigma-Aldrich
Carbon, mesoporous, hydrophilic pore surface
Sigma-Aldrich
Carbon, mesoporous
Sigma-Aldrich
Activated Charcoal Norit®, Norit® CA1, wood, chemically activated, powder
Sigma-Aldrich
Activated Charcoal Norit®, Norit® SX ultra, from peat, corresponds U.S. Food chemicals codex (3rd Ed.), steam activated and acid washed, highly purified, powder
Sigma-Aldrich
Activated Charcoal Norit®, Norit® GAC 1240W, from coal, for potable water processing, steam activated, granular
Sigma-Aldrich
Activated Charcoal Norit®, Norit® PK 1-3, from peat, steam activated, granular
Sigma-Aldrich
Activated Charcoal Norit®, Norit® SX2, powder, from peat, multi-purpose activated charcoal, steam activated and acid washed
Sigma-Aldrich
Activated Charcoal Norit®, Norit® RB3, for gas purification, steam activated, rod
Supelco
Hexamethyldisilazane, for GC derivatization, LiChropur, ≥99.0% (GC)
Sigma-Aldrich
Hexamethyldisilazane, produced by Wacker Chemie AG, Burghausen, Germany, ≥97.0% (GC)
Sigma-Aldrich
Hexamethyldisilazane, reagent grade, ≥99%
Sigma-Aldrich
Carbon nanofibers, pyrolitically stripped, platelets(conical), >98% carbon basis, D × L 100 nm × 20-200 μm
Sigma-Aldrich
Carbon nanofibers, graphitized, platelets(conical), >98% carbon basis, D × L 100 nm × 20-200 μm
Supelco
Activated Charcoal Norit®, Norit® RBAA-3, rod
Sigma-Aldrich
N,O-Bis(trimethylsilyl)acetamide, synthesis grade, ≥95%
Sigma-Aldrich
Methane-12C, 13C-depleted, 99.9 atom % 12C
Carbon - Vitreous, rod, 200mm, diameter 5.0mm, glassy carbon
Carbon - Vitreous, foam, 150x150mm, 0.05g.cmué, porosity 96.5%, 24 pores/cm
Carbon - Vitreous, foil, 10x10mm, thickness 1.0mm, glassy carbon
Carbon - Vitreous, rod, 200mm, diameter 7.0mm, glassy carbon
Carbon - Vitreous, foil, 10x10mm, thickness 4.0mm, glassy carbon
Carbon - Vitreous, rod, 100mm, diameter 1.0mm, glassy carbon
Carbon - Vitreous, rod, 50mm, diameter 1.0mm, glassy carbon
Carbon - Vitreous, foil, 25x25mm, thickness 0.5mm, glassy carbon
Supelco
N,O-Bis(trimethylsilyl)acetamide, for GC derivatization, LiChropur, ≥98.5% (GC)
Sigma-Aldrich
Hexamethyldisilazane, ReagentPlus®, 99.9%
Carbon - Vitreous, foam, 150x150mm, thickness 2.5mm, bulk density 0.05g/cm3, porosity 96.5%